A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

26/09/2024

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

Download

To receive OSE Immunotherapeutics’ latest news